All In MedTech

Device Trial Radar · NCT05742997

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

165

Planned (sponsor's estimate)

Start

Oct 1, 2021

Primary completion

Aug 31, 2023

Study completion Oct 31, 2023

Sponsor

Lead sponsor
Ziekenhuis Oost-LimburgAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 24, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Currently, the American College of Obstetricians and Gynecologists (ACOG) indicate in their most recent Practice Bulletin on the Management of Preterm Labor that many tests to identify women at risk of preterm birth have been proposed and evaluated; however, only ultrasonography and fetal fibronectin testing have been shown to have benefit. Ultrasonography to determine cervical length, fetal fibronectin testing, or a combination of both may be useful in determining which women are at high risk for preterm delivery. However, their clinical usefulness may rest primarily with their ability to identify women who are least likely to deliver (i.e. their negative predictive value). Therefore, there is an urgent need for a test with a high positive predictive value in order to accurately predict imminent delivery to allow for salutary intervention.

Conditions

  • Preterm Birth

Interventions

  • PartoSureDevice

    Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1

  • Fetal FibronectineDevice

    Diagnostic Kit for the Detection of Fetal Fibronectine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 48 hours
  2. Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 7 days
  3. Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ziekenhuis Oost-Limburg

    Genk, Limburg, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.